Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.

VPN usage in Turkey has spiked significantly following reports of social media restrictions and the arrest of President ...

Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral ...

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Phase 2 Drilling Program : Phase 2 drilling is set to begin soon, utilizing new road access and a higher-power NQ/HQ drill rig to target deeper mineralization and expand the 500m × 400m mineralized ...

Phase 2 Drilling Program: Phase 2 drilling is set to begin soon, utilizing new road access and a higher-power NQ/HQ drill rig to target deeper mineralization and expand the 500m × 400m mineralized ...

Mads Pedersen thrived in the wet and cold conditions, driving a relentless pace that shattered the peloton on the final climb ...

Persistent Link: https://ieeexplore.ieee.org/servlet/opac?punumber=9944983 ...

Data from the Phase 3 ICONIC-LEAD a study, presented as a late-breaking abstract at the 2025 American Academy of Dermatology (AAD) Annual Meeting, show once daily icotrokinra demonstrated significant ...

Incyte has since launched the TRuE-PN clinical trial series, consisting of the TRuE-PN1 (NCT05755438) and TRuE-PN2 (NCT05764161) trials, to examine the safety and efficacy of ruxolitinib cream for ...

Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...

PN Engage Private Limited is an Indian Non-Government Company. It's a private company and is classified as'company limited by shares'. Company's authorized capital stands at Rs 10.0 lakhs and has 10.0 ...